Cytokind’s Published Phase 1 Trial Results in COVID: NB-UVB reduced 28-day mortality by 60%
Cytokind's Phase 1 Trial Results Published in Experimental Dermatology. Narrowband ultraviolet B (NB-UVB) phototherapy reduced 28-day mortality by 60%. …
Cytokind, Inc. Announces Opening of the Adaptive Photo- Protection Clinical Trial for COVID-19 Patients
Ecosia shows ads in its SERPs, which it calls EcoAds. In order to show ads and search results it has partnered with Bing (we love Bing!). Through this model, Bing shares a portion of the revenue generated by these ads. …